The modified Glasgow prognostic score and C-reactive protein (CRP) levels are valuable and commonly used markers of systemic inflammation, which correlate with the prognosis of numerous human cancers, including pancreatic cancer. This evidence concerns the gene CRP and pancreatic neoplasm.